Get the Stockscreener App
6.66
2.46%
0.16
After Hours:
6.76
0.10
+1.50%
Quantum Biopharma Ltd stock is traded at $6.66, with a volume of 467.68K.
It is up +2.46% in the last 24 hours and down -10.12% over the past month.
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.
See More
Previous Close:
$6.50
Open:
$6.48
24h Volume:
467.68K
Relative Volume:
0.20
Market Cap:
$12.78M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+46.70%
1M Performance:
-10.12%
6M Performance:
+65.67%
1Y Performance:
+0.00%
1-Day Range:
$6.45
$7.50
1-Week Range:
$4.33
$8.60
52-Week Range:
$2.70
$18.00
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
6.66 | 12.78M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
163.75 | 73.33B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.13 | 47.80B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.37 | 46.89B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.67B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.53 | 13.99B | 612.78M | -86.37M | -62.91M | -0.87 |
Quantum Biopharma Ltd Stock (QNTM) Latest News
Quantum BioPharma Unaware of Any Material Change - Newsfile
Quantum BioPharma Provides Corporate Update - Yahoo Finance
Quantum BioPharma Ltd (NASDAQ: QNTM): A Bold Step into the Future of Biopharmaceutical Innovation - openPR
Quantum BioPharma Completes Phase 1 Trial Of Lucid-21-302 For Multiple Sclerosis Treatment - Nasdaq
Quantum Biopharma up in U.S. Pre-market, Says Phase 1 Lucid-MS Trial Completed With no Safety Concerns - Marketscreener.com
Quantum BioPharma Reports No Safety Concerns for Lucid-MS Following Successful Phase 1 Trial - Nasdaq
Quantum Biopharma Announces Completion of the Phase 1 - GlobeNewswire
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302 - Niagara Falls Review
Quantum BioPharma expands cryptocurrency holdings By Investing.com - Investing.com Nigeria
Quantum BioPharma Continues to Diversify its Treasury with - GlobeNewswire
Quantum BioPharma Up 10% as Purchases Another US$1 Million Worth of Bitcoin, Other Cryptocurrencies - Marketscreener.com
Quantum BioPharma Soars 62% After Positive Clinical Trial Results for Unbuzzd Supplement - HPBL
Quantum BioPharma expands cryptocurrency holdings - Investing.com India
Quantum BioPharma Expands Cryptocurrency Holdings - TipRanks
Quantum BioPharma Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies - The Manila Times
Quantum BioPharma Shares Soar 95% Following Breakthrough Clinical Trial Results for unbuzzd™ - HPBL
Best Cannabis Stocks To ConsiderFebruary 14th - MarketBeat
Quantum BioPharma unbuzzd™ Clinical Trial Results Show Promising Benefits in Alcohol Intoxication and Hangover Relief – market - HPBL
Quantum BioPharma (QNTM) Stock Soars 95% After Breakthrough Alcohol Metabolism Supplement Results - HPBL
Best Cannabis Stocks To Consider – February 14th - Defense World
Promising Cannabis Stocks To ConsiderFebruary 11th - MarketBeat
Top Cannabis Stocks To Consider – February 13th - Defense World
Quantum Biopharma Ltd Stock (QNTM) Financials Data
There is no financial data for Quantum Biopharma Ltd (QNTM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.19%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):